'Current study objectives' presentation slideshows

A Firm-Based Freight Demand Modeling Framework:

389 views • 25 slides

Goss GD et al. Proc ASCO 2010;Abstract LBA7005.

A Phase III Randomized, Double-Blind, Placebo-Controlled Trial of the Epidermal Growth Factor Receptor Inhibitor Gefitinb in Completely Resected Stage IB-IIIA Non-Small Cell Lung Cancer (NSCLC): NCIC CTG BR.19. Goss GD et al. Proc ASCO 2010;Abstract LBA7005. Introduction.

241 views • 10 slides

Albain KS et al. Lancet Oncol 2010;11(1):55-65. Albain KS et al.

Prognostic and Predictive Value of the 21-Gene Recurrence Score Assay in Postmenopausal Women with Node-Positive, Estrogen- Receptor-Positive Breast Cancer on Chemotherapy: A Retrospective Analysis of a Randomised Trial. Albain KS et al. Lancet Oncol 2010;11(1):55-65. Albain KS et al.

404 views • 9 slides

Bergh J et al. SABCS 2009;Abstract 23.

First Results from FACT - An Open-Label, Randomized Phase III Study Investigating Loading Dose of Fulvestrant Combined with Anastrozole versus Anastrozole at First Relapse in Hormone Receptor Positive Breast Cancer . Bergh J et al. SABCS 2009;Abstract 23. Introduction.

266 views • 6 slides

Baselga J et al. SABCS 2009;Abstract 45.

SOLTI-0701: A Multinational Double-Blind, Randomized Phase 2b Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo in Combination with Capecitabine in Patients with Locally Advanced or Metastatic Breast Cancer. Baselga J et al. SABCS 2009;Abstract 45. Introduction.

232 views • 6 slides